Preclinical Research

  • Preclinical Research
  • Exclusive Insights on Novel Surgical Solutions in Preclinical Studies


    Surgical Models Tailored to Your Needs

    Check out our latest on-demand webinar presented by Dr. Emily Griffith, DVM, Associate Director, Surgical Services, where we explore how Altasciences’ surgical experts support toxicology and safety pharmacology studies through surgical procedures and model development to achieve your research objectives.

    Webinar: Innovative Surgical Solutions: Safety Assessment Studies at Altasciences

    Want to learn more? Speak with one of our experts.

    Related resources you may be interested in:

    Altasciences' Manufacturing Services


    Ria Falvo and Rina Massarelli in Toronto, Ontario

    Ria Falvo, Director of Reporting, and Rina Massarelli

    Fast-Track Gene Therapy Discovery With Easy Access to NHPs


    Speed Up Your Gene Therapy Discovery at Our Sacramento Site

    Do you need quick, hassle-free access to a large pool of nonhuman primates (NHPs) for your gene therapy discovery work? We make it easy—just a short drive to our Sacramento (California) site, and you can be in our vivarium observing the dosing of your discovery study firsthand. Early and accurate data is closer than you think!

    Backed by decades of experience and expertise, we offer:

    • Vector development and optimization
    • PK/PD
    • Biodistribution
    • Efficacy evaluations
    • Dose-response analysis

    Benefit from access to 800 readily available NHPs:

    • No quarantine requirements
    • Rapid start-up times
    • Easy communication—no significant time difference

    Get your discovery studies underway without delays. Contact us now to get started.

    Related resources you may be interested in:

    Embedded Manufacturing Services


    Immunogenicity Data Delivered Without Delay


    Preclinical Assays for Immunogenicity Testing in Clinical Trials

    Whether developing a vaccine, biologic, or gene therapy, immunogenicity testing is required for regulatory approval and is critical for determining the safety and efficacy of your product.

    Our scientific experts will ensure your nonclinical assays are adapted and validated for your clinical trials, with a tailored bioanalytical program designed for your drug type and study purpose. We focus on the right PK/PD endpoints to ensure regulatory and bioanalytical standards are met.

    For more information on assessing immunogenicity, please browse and bookmark these resources.

    Immunomodulation Assesments for Clinical Trials

    A Comprehensive Guide to Immunomodulation

    In this issue, find out more about the standard classes of immunomodulators, advanced bioanalytical methods, and case studies with practical insights.

    Developing a Strategic Approach to Immunogenicity Assesment

    Purposes and Challenges for Nonclinical and Clinical Studies

    In this edition of The Altascientist, learn about the different purposes and challenges of validating immunogenicity assays to strategically develop a safe and quick approach to support nonclinical and clinical studies.

    Facing Bioanalytical Challenges

    Challenges Encountered in Anti-Drug Antibody Assays

    Find out how we have implemented strategies to overcome matrix interferences observed in disease populations. This allows us to assess immunogenicity in complex clinical studies targeting diverse populations, ensuring a comprehensive understanding of each therapeutic's impact.

    Immunogenicity Testing Services

    Tailored Immunogenicity Testing Services

    We cover all essential assays, from characterization to binding specificity, isotyping, and NAbs, while ensuring our approach is adapted to your drug's mechanism of action.

    Ready to book your study or have a question about your study? Speak with one of our experts.


    The Austin skyline along the Colorado river
    The ACT 2024 meeting took place at JW Marriott in Austin, TX

    My fellow Altasciences colleagues and I recently attended the 2024 annual Ame

    How to Decrease Your Test Article Usage in Preclinical Studies


    Less is More With the Sinclair Nanopig™

    Did you know that using the Sinclair Nanopig™ swine model can decrease your test article usage by up to 50% compared to the Göttingen™ minipig and dog?

    Let’s get your project underway with cost-effective solutions and reliable results.
    Speak with one of our experts today.

    Altasciences Sinclair Nanopig Comparison

    Related resources you may be interested in:

    Tailored Manufacturing and Analytical Testing for Your Molecules


    A CDMO You Can Count On.

    From discovery to commercialization, our manufacturing team is dedicated to delivering high-quality and FDA-compliant products, every time.

    Discover our full range of drug development, manufacturing, and analytical testing services for oral solid dosage forms, injectables, creams, and gels―including the shipping and handling of highly potent compounds and controlled substances.

    With over 25 years of experience, in-house R&D and formulation laboratories, innovative platforms and technology, and an exceptional team of scientists, we are committed to providing you with the best manufacturing solutions for your program.

    You can count on us!

    Speak with one of our experts today to get started.

    Related resources that may interest you:

    Fast Track Your 2025 Drug Development Program


    Get a Head Start on Your Preclinical Studies

    With four strategically placed preclinical research facilities throughout North America, we can get your investigational new drug (IND) and clinical trial application (CTA) studies underway in 8-10 weeks!

    We offer a full range of in vivo non-GLP and GLP preclinical studies in both rodent and non-rodent species, to assess the safety of your small and large molecules in support of upcoming first-in-human clinical trials.

    Our IND/CTA-enabling studies include:

    Time is of the essence―let’s get started!

    Related resources that may interest you:


    From AAV to Biomarkers—Your 2025 Roadmap


    Support for Your Early-Phase Gene Therapy Program

    At Altasciences, we are committed to advancing gene therapies with precision and efficiency. In addition to hundreds of pre-screened AAV nonhuman primates (NHPs) available for gene therapy programs and decades of bioanalytical, nonclinical, and clinical expertise―we’ve compiled a comprehensive list of resources below:

    Key Considerations for Nonclinical AAV Gene Therapy Development

    A Comprehensive Guide to Gene Therapy and Improving AAV Efficiency

    Learn more about our track record, expertise in navigating regulatory requirements, and how we ensure the safety and efficacy of AAV-based therapies (three case studies included).


    Screening for Pre-Existing Antibodies to Adenovirus for Nonclinical Gene Tehrapy Programs

    In-House AAV Pre-Screening

    Detailed information on our in-house AAV pre-screening methods for removing nonhuman primates from toxicology studies if they have antibodies against AAV8 serotypes. It covers two main assays: total antibody screening (TAb) and neutralizing antibody screening (NAb).


    Nonclinical Studies in Cell and Gene Therapy

    Expert Insights on Cell and Gene Therapy Development

    This scientific journal reviews considerations for nonclinical cell and gene therapy development, including expert approaches to mitigate complex challenges, improve study efficiency, and maximize translational opportunities to first-in-human trials.


    Translational Biomarker Assays by Indication

    Altasciences’ Biomarkers by Indication

    Our expertise in biomarker analysis supports critical go/no-go decision making by providing insight into a drug’s efficacy, safety, and mechanism of action. Assessed early in the drug development process, biomarker assays can validate targets and identify potential toxicity.


    Ready to get your gene therapy development program started? Speak with one of our experts.


    Subscribe to Preclinical Research